Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies

The treatment of advanced gastrointestinal (GI) cancers has become increasingly molecularly driven. Molecular profiling for HER2 and PD-L1 status is standard for metastatic gastroesophageal (GEJ) cancers to predict benefits from trastuzumab (HER2-targeted therapy) and pembrolizumab (anti-PD-1 therap...

Descripción completa

Detalles Bibliográficos
Autores principales: C. Huynh, Jasmine, Schwab, Erin, Ji, Jingran, Kim, Edward, Joseph, Anjali, Hendifar, Andrew, Cho, May, Gong, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281439/
https://www.ncbi.nlm.nih.gov/pubmed/32384640
http://dx.doi.org/10.3390/cancers12051168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281439/
https://www.ncbi.nlm.nih.gov/pubmed/32384640
http://dx.doi.org/10.3390/cancers12051168

Ejemplares similares